Análisis Argos
FMS
FMSBarata · ojo al riesgo
Fresenius Medical Care AG & Co. KGaA · Healthcare
US$ 24.75
precio al 2026-07-28
Valor justo Argos*
US$ 42–48
vs. su valor justo
46% por debajo
Score Argos
67/100
Barata · ojo al riesgo
LA RESPUESTA
El mercado la precia para que se encoja 16.5% al año — menos de lo que viene demostrando (2.8%). Un negocio de calidad castigado por expectativas pesimistas: por eso está entre las llamadas de Argos. Ojo: tiene señales de riesgo en sus números — es barata con asterisco.
Recompensas
Cotiza por debajo de su valor justo: el mercado le pide menos crecimiento del que viene demostrando.
Las ganancias crecieron 82% el último año.
Reparte dividendo sostenible (3.49%).
Riesgos
!Balance frágil: la deuda pesa sobre el negocio.
!Crecimiento estancado o en baja.
VALOR4/6FUTURO2/6PASADO3/6SALUD1/6DIVIDENDO5/6
El Iris de calidad
VALOR4/6FUTURO2/6PASADO3/6SALUD1/6DIVIDENDO5/6
ValorCotiza por debajo de su valor justo
FuturoCrecimiento moderado
PasadoHistorial aceptable
SaludBalance frágil
DividendoDevuelve capital al accionista
Score Argos67de 100Barata · ojo al riesgo
Ingresos1%
US$ 19.6 B
Margen operativo22%
9.3%
Flujo de caja libre1%
US$ 1.7 B
Deuda neta
US$ 9.2 B
Lo esencial, sin ruido
Cap. de mercadoUS$ 13.3B
P/E13.6x
EV/EBITDA6.8x
FCF yield12.8%
ROIC6.1%
Margen operativo9.3%
Crecim. ingresos+1.5%/año
Piotroski F8/9
Competidores

Los rivales, con el mismo ojo

El Iris de calidad de cada competidor, lado a lado. Tocá uno para ver su análisis.

Novedades

Noticias recientes

seekingalpha.com · 11 jul
Fresenius Medical: High Yield, Utilities-Like Stock At Valuation Lows
FMS is a defensive dialysis services provider with stable and recurring demand and regulated pricing. Profitability is recovering as FME25+ cost savings flow through the business. The stock offers attractive shareholder returns through high free cash flow, dividends, and large buybacks.
zacks.com · 8 jul
Reasons to Retain Fresenius Medical Stock in Your Portfolio for Now
FMS??? margin gains, HighVolumeHDF rollout and AI-driven care are boosting momentum, but reimbursement and volume risks remain.
zacks.com · 23 jun
DVA vs. FMS: Which Dialysis Leader Is Better Positioned Now?
DaVita and Fresenius Medical Care are taking different paths in kidney care, but which stock offers stronger upside now? Let's dive in.
newsfilecorp.com · 22 jun
Focus Graphite Announces SEDAR+ Filing of the NI 43-101 Technical Report with the Updated Mineral Resource for the Lac Tetepisca Project
One of the Largest Identified Graphite Deposits Globally with 120.2 Mt Indicated at 10.27% Cg and 24.1 Mt Inferred at 9.88% Cg, Containing 14.7 Mt of In-Situ Graphite Ottawa, Ontario--(Newsfile Corp. - June 22, 2026) - Focus Graphite Inc. (TSXV: FMS) (OTCQB: FCSMF) (FSE: FKC0) ("Focus" or the "Company"), a Canadian developer of high-grade flake graphite deposits and advanced graphite materials for battery, defence, and industrial applications, is pleased to announce that it has filed the report on SEDAR+ for the upgraded mineral resource estimate ("MRE") on its 100%-owned Lac Tetepisca Project (the "Project") in Quebec. The Project lies within the Nitassinan (ancestral land) of the Pessamit Innu First Nation of Betsiamites, Quebec.
newsfilecorp.com · 15 jun
Focus Graphite Completes Final Major ESIA Technical Study, Advancing Lac Knife Toward Permitting
Hydrogeological Assessment Concludes Multi-Year Environmental Program and Supports Upcoming ESIA Submission Ottawa, Ontario--(Newsfile Corp. - June 15, 2026) - Focus Graphite Inc. (TSXV: FMS) (OTCQB: FCSMF) (FSE: FKC0) ("Focus" or the "Company") a Canadian developer of high-grade flake graphite deposits and advanced graphite materials for battery, defence, and industrial applications, is pleased to announce the completion of the Hydrogeological Assessment (the "Assessment" or the "Study") for its wholly-owned Lac Knife Graphite Project ("Lac Knife" or the "Project"), concluding a multi-year environmental program and completing the major technical work required to support the Company's Environmental and Social Impact Assessment ("ESIA") submission. Completed by Yves Leblanc, P.Geo.
zacks.com · 8 jun
FMS and Home Dialysis: How 5008X Could Reset Demand
FMS scales 5008X high-volume HDF and expands home dialysis, aiming for benefits later in 2026 and a bigger payoff in 2027+.
zacks.com · 5 jun
FMS Launches kinexus Digital Platform for Home Dialysis Care
Fresenius Medical Care launches kinexus, a home dialysis platform integrating remote monitoring, prescription management and supply ordering for PD and HHD.
prnewswire.com · 3 jun
Fresenius Medical Care launches kinexus worldwide, a unified digital platform to support home dialysis
Global launch of a single, integrated digital platform connecting remote therapy monitoring and operational workflows for home dialysis programs Designed to simplify care processes for healthcare teams and their patients to support high-quality, personalized care for patients dialyzing at home Enables managing peritoneal dialysis and home hemodialysis therapies across Fresenius Medical Care's global home dialysis portfolio in one digital platform BAD HOMBURG, Germany, June 3, 2026 /PRNewswire/ -- Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, today announced the global launch of kinexus, a unified digital platform designed to support home dialysis programs and strengthen connected, patient-centered care. With kinexus, Fresenius Medical Care (FME) is advancing connected home dialysis care by bringing together digital modules supporting peritoneal dialysis (PD) and home hemodialysis (HHD) within a single, unified platform.

* Valor justo Argos: estimación educativa del valor intrínseco según el propio flujo de caja de la empresa y su capacidad de crecimiento — no un precio objetivo ni una recomendación. Esto es información y educación, no asesoría de inversión. Rendimiento pasado no garantiza resultados futuros.